J
Jiandong Tong
Researcher at Peking Union Medical College
Publications - 4
Citations - 729
Jiandong Tong is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 543 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li,Shukui Qin,Jianming Xu,Jianping Xiong,Changping Wu,Yuxian Bai,Wei Liu,Jiandong Tong,Yunpeng Liu,Rui-Hua Xu,Zhehai Wang,Qiong Wang,Xuenong Ouyang,Yan Yang,Yi Ba,Jun Liang,Xiaoyan Lin,Deyun Luo,Rongsheng Zheng,Xin Wang,Guoping Sun,Liwei Wang,Leizhen Zheng,Hong Guo,Jingbo Wu,Nong Xu,Jianwei Yang,Hong-gang Zhang,Ying Cheng,Ningju Wang,Lei Chen,Zhining Fan,Piaoyang Sun,Hao Yu +33 more
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Journal ArticleDOI
An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis
TL;DR: In this paper , the authors performed a meta-analysis to clarify the prognostic significance of proton pump inhibitor (PPI) use in advanced solid cancer patients receiving ICI therapy.
Journal ArticleDOI
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
Shukui Qin,Weijia Fang,Zhenggang Ren,Ou Shuangyan,Ho Yeong Lim,Feng Zhang,Hye Jin Choi,Jiandong Tong,Min Tao,Aibing Xu,Ashley Cheng,Chang Hsien Lu,Chang Fang Chiu,Mohamed Ibrahim Bin A. Wahid,Shital Kamble,Josephine M. Norquist,Wenhe Zhong,Chen Li,Zhendong Chen +18 more
TL;DR: There was a statistically significant difference in LSM for change from BL to wk 12, between the two arms for the QLQ-C30 GHS/QoL score and EQ-5D VAS score, with more decline observed in the PBO arm.
Proceedings ArticleDOI
673 Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II study
Xiaohua Wu,Lingfang Xia,Jing Wang,Chunyan Wang,Qingming Zhang,Jianqing Zhu,Qunxian Rao,Huijun Cheng,Zheng Liu,Yongmei Yin,Xiaohong Ai,Kurban Gulina,Hong Zheng,Xiaoyong Luo,B Chang,Lin Li,Haiyan Liu,Yunxia Li,Ge Lou,Qi Zhou,Yanling Zhu,Ze-Min Xiao,Jiandong Tong,Ke Wang,Jie Chen,Xia Wang,Li-yun Song,Zhixiao Wei,Yi-jing Ye,Jiman Zhu +29 more
TL;DR: Zimberelimab is a fully human anti-PD-1 monoclonal antibody with high affinity and selectivity for PD-1 as mentioned in this paper , which has been shown to have durable antitumor activity and an acceptable safety profile in patients with recurrent or metastatic cervical cancer that had progressed after first- or subsequent-line platinum-containing standard chemotherapy.